MAA
BPMC

Mraz Amerine & Associates’s Blueprint Medicines BPMC Stock Holding History

Mraz Amerine & Associates’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,391
Closed -$478K – 192
2025
Q1 		$478K Buy
5,391
+45
+0.8% +$4.39K 0.08% 112
2024
Q4 		$466K Sell
5,346
-435
-8% -$39.8K 0.08% 111
2024
Q3 		$535K Sell
5,781
-167
-3% -$16.6K 0.1% 111
2024
Q2 		$641K Sell
5,948
-128
-2% -$12.8K 0.13% 103
2024
Q1 		$576K Sell
6,076
-235
-4% -$20.2K 0.11% 108
2023
Q4 		$582K Hold
6,311
– – 0.12% 105
2023
Q3 		$317K Sell
6,311
-260
-4% -$13.9K 0.07% 134
2023
Q2 		$415K Hold
6,571
– – 0.1% 117
2023
Q1 		$296K Buy
+6,571
New +$296K 0.07% 133

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mraz Amerine & Associates's BPMC Position: Q2 2025 in Review

Mraz Amerine & Associates sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 5,391 shares — an estimated $478K sold.

Mraz Amerine & Associates first reported a position in BPMC in Q1 2023 and held it in 9 quarters. The position peaked at $641K in Q2 2024. 355 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Mraz Amerine & Associates reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Mraz Amerine & Associates sold 5,391 Blueprint Medicines shares in Q2 2025, an estimated $478K.
  • Mraz Amerine & Associates first reported a position in Blueprint Medicines in Q1 2023 and held it in 9 quarters.
  • Mraz Amerine & Associates's Blueprint Medicines position peaked at $641K in Q2 2024.
  • 355 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Mraz Amerine & Associates's 13F filing for Q2 2025, filed 23 Jul 2025.